Geneva, March 23 -- International Clinical Trials Registry received information related to the study (ChiCTR2600119918) titled 'A Study on the Safety, Tolerability, and Preliminary Efficacy of CREPT-618 in Patients with Metabolic Dysfunction-Associated Steatohepatitis' on March 5.
Study Type: Interventional study
Study Design:
Non randomized control
Primary Sponsor: Tianjin Fifth Central Hospital
Condition:
Metabolic dysfunction-associated fatty liver disease
Intervention:
Group 2:CREPT-618, Dosage of 1.5mg/kg
Recruitment Status: Not Recruiting
Phase: N/A
Date of First Enrollment: 2026-03-09
Target Sample Size: Group 2:6;Group 1:6;
Countries of Recruitment:
China
To know more, visit https://www.chictr.org.cn/showproj.htm...